Biomarkers guide personalized treatment for aggressive prostate cancer

A clinical trial revealed that biomarkers may hold the key to more effective, personalized treatments for aggressive prostate cancer, potentially preventing recurrence. Researchers at UC Davis found that analyzing circulating tumor DNA (ctDNA) could help track tumor evolution and identify patients who might benefit from targeted therapies before surgery using the drug niraparib. The study focused on men with specific gene mutations. The findings, to be presented at the ASCO conference, suggest that genetic testing and blood-based monitoring could improve prostate cancer treatment, though responses to the drug varied among patients.